Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

BASAGLAR

×

Overview

What is BASAGLAR?

BASAGLAR (insulin glargine injection) is a long-acting insulin for subcutaneous use. Insulin glargine is a recombinant human insulin analog . BASAGLAR is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, insulin glargine is 21-Gly-30-a-L-Arg-30b-L-Arg-human insulin and has the empirical formula CHNOS and a molecular weight of 6063. Insulin glargine has the following structural formula:

BASAGLAR is a clear, colorless, sterile aqueous solution of insulin glargine. Each milliliter of BASAGLAR (insulin glargine injection) contains 100 units (3.6378 mg) insulin glargine.

The 3 mL BASAGLAR KwikPen contains the following inactive ingredients per mL: 30 mcg zinc, 2.7 mg metacresol, 17 mg glycerin, and water for injection.

The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. BASAGLAR has a pH of approximately 4.



What does BASAGLAR look like?



What are the available doses of BASAGLAR?

Injection: 100 units/mL (U-100) in 3 mL prefilled BASAGLAR KwikPen delivery device. ()

What should I talk to my health care provider before I take BASAGLAR?

How should I use BASAGLAR?

BASAGLAR is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.

Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, prior insulin use. (, , )

Administer subcutaneously once daily at any time of day, but at the same time every day. ()

Rotate injection sites to reduce the risk of lipodystrophy. ()

Closely monitor glucose when converting to BASAGLAR and during initial weeks thereafter. ()

Do not dilute or mix with any other insulin or solution. ()


What interacts with BASAGLAR?

Sorry No Records found


What are the warnings of BASAGLAR?

Sorry No Records found


What are the precautions of BASAGLAR?

Sorry No Records found


What are the side effects of BASAGLAR?

Sorry No records found


What should I look out for while using BASAGLAR?

BASAGLAR is contraindicated:


What might happen if I take too much BASAGLAR?

Excess insulin administration relative to food intake, energy expenditure, or both may lead to severe and sometimes prolonged and life-threatening hypoglycemia and hypokalemia . Mild episodes of hypoglycemia can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or physical activity level may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.


How should I store and handle BASAGLAR?

Do not freeze BASAGLAR. Do not use BASAGLAR if it has been frozen. BASAGLAR must be protected from direct heat and light. Do not use after the expiration date. Storage conditions are summarized in the following table: Do not freeze BASAGLAR. Do not use BASAGLAR if it has been frozen. BASAGLAR must be protected from direct heat and light. Do not use after the expiration date. Storage conditions are summarized in the following table: Do not freeze BASAGLAR. Do not use BASAGLAR if it has been frozen. BASAGLAR must be protected from direct heat and light. Do not use after the expiration date. Storage conditions are summarized in the following table: Do not freeze BASAGLAR. Do not use BASAGLAR if it has been frozen. BASAGLAR must be protected from direct heat and light. Do not use after the expiration date. Storage conditions are summarized in the following table: Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017Lopressor Tabletsmetoprolol tartrate USP TabletsTablets 50 mg         Bottles of 100………………………………………….………NDC 30698-458-01Tablets 100 mg         Bottles of 100………………………………………………….NDC 30698-459-01Storage:  Dispense in a tight, light-resistant container (USP).Manufactured for and Distributed by:Product of Spain© 2017 Validus Pharmaceuticals LLC60025-01September 2017


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.

Non-Clinical Toxicology
BASAGLAR is contraindicated:

Catecholamine-depleting drugs:







Calcium channel blockers:











Alpha-adrenergic agents:

Ergot alkaloid:

Dipyridamole:

BASAGLAR KwikPens must never be shared between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.

The following adverse reactions are discussed elsewhere:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).